EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study

Ratidzo Chirimo iD, Danai Tavonga Zhou, Tinashe Mudzviti iD, Ian Machingura Ruredzo, Justen Manasa, Charles Chiedza Maponga, Zvenyika Alfred Reginald Gomo, Exnevia Gomo, Gene D Morse

PLOS One · 2026

DOI: 10.1371/journal.pone.0359196 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift PLOS One, 2026. Verfasst von Ratidzo Chirimo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe. Hauptthemen laut MEDLINE: Dyslipidemias, Piperazines, HIV Infections, Hyperglycemia. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, FIC NIH HHS, Sub Saharan African Network for TB/HIV Research Excellence - SANTHE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dolutegravir (DTG)-based antiretroviral therapy (ART) is now the preferred first-line regimen for people living with HIV (PLWH) globally, including in Zimbabwe, which has an estimated adult HIV prevalence of 12.9%. While DTG offers a high genetic barrier to resistance and favourable tolerability, it has been linked to metabolic abnormalities — including abdominal obesity, hypertension, dyslipidaemia, and impaired glucose regulation — that cluster together and increase the risk of cardiovascular disease and type 2 diabetes. Data on this burden remain limited in Zimbabwe. We conducted an exploratory, hypothesis-generating cross-sectional study to estimate the burden of hyperglycaemia and dyslipidaemia, and to identify their correlates, among PLWH on first-line DTG-based ART.

Objective

This study aimed to determine the burden and correlates of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on first-line DTG-based ART.

Methods

A cross-sectional study was conducted from 20 January 2025–13 February 2025. The study participants were 171 PLWH receiving first-line DTG-based treatment at Parirenyatwa Group of Hospitals, in Harare, Zimbabwe. A structured questionnaire was administered to collect demographics, lifestyle information, clinical parameters and anthropometric indices. We calculated body mass index (BMI). Blood pressure measurements were taken with the participant in a resting position. Blood samples were collected and we measured HbA1c, glucose, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C).

Results

Of the 171 participants, 67.8% were female, with a median age of 42.1 years (IQR 32.4–50.2). The majority had at least secondary education, and few were smokers (n = 9), while 23% reported alcohol use and 62.2% reported no regular exercise. Over half (57.9%) were overweight or obese, and 39.8% were hypertensive. The prevalence of dyslipidaemia and hyperglycaemia was 74.3% and 13.4%, respectively, with insulin resistance present in 56.1%. Non-ideal HDL-C was the most common lipid abnormality (50.5%), followed by raised LDL-C (33.3%), raised triglycerides (16%), and hypercholesterolaemia (10.3%). On multivariate analysis, increasing age was independently associated with hyperglycaemia (AOR 1.08, 95% CI 1.03–1.13, p = 0.002), while elevated blood pressure was independently associated with dyslipidaemia (AOR 2.64, 95% CI 1.03–6.78, p = 0.043).

Conclusion

Dyslipidaemia and hyperglycaemia are highly prevalent among Zimbabwean adults on DTG-based ART, with elevated blood pressure and increasing age as key independent correlates. As this population ages on long-term ART, routine, integrated screening of BMI, blood pressure, glucose, and lipid profile is essential to mitigate cardiometabolic risk and sustain the success of DTG-based ART in Zimbabwe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasPiperazinesHIV InfectionsHyperglycemiaHeterocyclic Compounds, 3-RingOxazinesPyridonesHumansFemaleCross-Sectional StudiesAdultZimbabweMaleDolutegravirMiddle Aged

Substanzen

PiperazinesHeterocyclic Compounds, 3-RingDolutegravirOxazinesPyridones

Autor:innen und Institutionen

  • Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • School of Pharmacy, University of the Western Cape, Cape Town, South Africa.
  • Newlands Clinic, Harare, Zimbabwe.
  • Centre for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, United States of America.

ORCID-Profile: Ratidzo Chirimo, Tinashe Mudzviti

Förderung

  • Wellcome Trust
  • FIC NIH HHS
  • Sub Saharan African Network for TB/HIV Research Excellence - SANTHE
  • National Institutes of Health (NIH) Fogarty International Centre

Zitieren

APA

Chirimo, R., Zhou, D. T., Mudzviti, T., Ruredzo, I. M., Manasa, J., Maponga, C. C., Reginald Gomo, Z. A., Gomo, E., & Morse, G. D. (2026). Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study. PLOS One. https://doi.org/10.1371/journal.pone.0359196

Vancouver

Chirimo R, Zhou DT, Mudzviti T, Ruredzo IM, Manasa J, Maponga CC, et al. Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study. PLOS One. 2026. doi:10.1371/journal.pone.0359196

BibTeX
@article{Chirimo2026,
  author = {Chirimo, Ratidzo and Zhou, Danai Tavonga and Mudzviti, Tinashe and Ruredzo, Ian Machingura and Manasa, Justen and Maponga, Charles Chiedza and Reginald Gomo, Zvenyika Alfred and Gomo, Exnevia and Morse, Gene D},
  title = {Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0359196}
}
Kostenlos starten →